Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYSE: NYXH) is a pioneering health technology company focused on innovative treatments for sleep disordered breathing, particularly Obstructive Sleep Apnea (OSA). This page serves as the definitive source for official updates about their FDA-cleared Genio neurostimulation system, financial developments, and clinical research progress.
Investors and medical professionals will find curated press releases covering regulatory milestones, partnership announcements, and quarterly earnings reports. All content is sourced directly from company filings and verified channels to ensure accuracy.
Key focus areas include updates about international market expansions, clinical trial outcomes for OSA therapies, and technological enhancements to the Genio platform. Bookmark this page to stay informed about Nyxoah's progress in developing patient-centric solutions for chronic sleep conditions.
Nyxoah (NASDAQ: NYXH), a medical technology company focused on Obstructive Sleep Apnea (OSA) treatment, has announced preliminary Q2 2025 results. The company achieved revenue of €1.3 million, marking a 73% year-over-year increase. Operating expenses rose 50% to €20.7 million.
Key developments include FDA approval of the Genio® system for moderate to severe OSA patients with AHI between 15 and 65. The company maintains €43.0 million in cash and equivalents, with access to an additional €27.5 million in debt facility. Nyxoah plans to conclude ACCCESS trial enrollment early while maintaining the study's co-primary endpoints. The company faces a patent infringement lawsuit from Inspire Medical Systems and is reorganizing its R&D operations from Israel to the U.S. and Belgium.
Nyxoah (NASDAQ: NYXH) has received FDA approval for its Genio® system, a breakthrough treatment for moderate to severe Obstructive Sleep Apnea (OSA). The approval covers patients with an Apnea-Hypopnea Index (AHI) between 15 and 65.
The Genio system represents a novel approach to hypoglossal nerve stimulation, featuring bilateral stimulation and a unique leadless design that is MRI compatible. The system's efficacy was demonstrated in the DREAM pivotal trial, achieving a 63.5% AHI responder rate and an impressive 70.8% median AHI reduction.
Notably, the system showed consistent effectiveness across all sleeping positions, with a 66.6% median AHI reduction in supine position and 71.0% reduction in non-supine position. The company has officially launched its U.S. commercialization efforts.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has disclosed updated information regarding its voting rights and shares as required by Belgian law. The company reported a share capital of EUR 6,432,066.28 with 37,441,140 ordinary shares, each carrying one voting right. Additionally, there are 2,793,941 subscription rights not yet issued, excluding 493,057 subscription rights that were issued but not yet granted.
Nyxoah (NASDAQ:NYXH), a company focused on developing innovative treatments for Obstructive Sleep Apnea (OSA) through neuromodulation, has scheduled its Q2 2025 earnings release for August 18, 2025.
The company will host a conference call with management on the same day at 10:30pm CET / 4:30pm ET. Investors can access the call through the company's Investor Relations webpage or via a direct webcast link. Those planning to ask questions during the call should register at least 10 minutes before the start time using a separate registration link.
A replay of the webcast will be made available shortly after the call concludes.Nyxoah (NASDAQ:NYXH) announced the publication of its DREAM pivotal study data in the Journal of Clinical Sleep Medicine, showcasing comprehensive 12-month safety and efficacy results for its Genio® system in treating Obstructive Sleep Apnea (OSA).
The study demonstrated strong results with 63.5% AHI responder rate and 71.3% ODI responder rate. Patient engagement was remarkable, with 84.3% of participants using the device more than 4 hours in over 70% of nights, and 90% of patients expressing satisfaction. The device showed a 66.6% median reduction in supine AHI at 12 months.
Safety results aligned with other neuromodulation therapies, showing 11 serious adverse events in ten subjects (8.7% SAE rate), with only three being device-related. Quality-of-life outcomes improved significantly, with a 2.3-point increase in FOSQ assessment and 3.4-point reduction in Epworth Sleepiness Score.
Nyxoah (NASDAQ/Euronext: NYXH) has disclosed its updated share capital and voting rights information as of June 27, 2025. The company's share capital stands at EUR 6,431,121.38 with a total of 37,435,640 ordinary shares, each carrying one voting right. Additionally, there are 2,822,816 subscription rights not yet issued, excluding 478,057 subscription rights that were issued but not yet granted.
Nyxoah SA (NYXH), a medical technology company focused on developing innovative treatments for Obstructive Sleep Apnea (OSA), has announced its participation in the upcoming Jefferies Global Healthcare Conference in New York from June 3-5, 2025. CEO Olivier Taelman will deliver a corporate presentation on June 4, 2025, at 4:55pm ET. The presentation will be accessible via webcast on Nyxoah's Investor Relations website's Events section. The company will also be available for one-on-one meetings with institutional investors during the conference.
Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) has released an update on its share capital and voting rights structure as of May 23, 2025. The company's share capital stands at EUR 6,430,026.16. The total number of securities carrying voting rights is 37,429,265 ordinary shares, with an equal number of voting rights. Additionally, there are 2,854,068 subscription rights to securities not yet issued, excluding 478,057 subscription rights that were issued but not yet granted.
FAQ
What is the current stock price of NYXOAH S A (NYXH)?
What is the market cap of NYXOAH S A (NYXH)?
